Teriflunomid - Resultados da pesquisa

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - preparações antianêmicas - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

União Europeia - português - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - esclerose múltipla - imunossupressores seletivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

União Europeia - português - EMA (European Medicines Agency)

ponvory

janssen-cilag international n.v. - ponesimod - esclerose múltipla remitente-recorrente envio - imunossupressores - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.